Gentamycin Sulfate Injection

This product is an aminoglycoside antibiotic. It has good antibacterial effects on various Gram-negative and Gram-positive bacteria, and has good antibacterial effects on various Enterobacteriaceae such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Enterobacter, Serratia and Pseudomonas aeruginosa. Neisseria and Haemophilus influenzae are moderately sensitive to this product. It also has a certain effect on Brucella, Yersinia pestis, Acinetobacter and Campylobacter fetus. It has a good antibacterial effect on about 80% of methicillin-sensitive strains of Staphylococcus (including Staphylococcus aureus and coagulase-negative Staphylococcus), but methicillin-resistant strains are mostly resistant to this product. It has a poor effect on Streptococcus and Streptococcus pneumoniae, and Enterococcus is mostly resistant to this product. When this product is used in combination with β-lactams, most of them can obtain synergistic antibacterial effects. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins. In recent years, the number of Gram-negative bacteria resistant to gentamicin has increased significantly.

The chemical name of gentamicin sulfate is N-(5-methoxy-2-pyrimidinyl)-4-aminobenzenesulfonamide.

This product is a colorless or almost colorless clear liquid.

1. It is suitable for the treatment of severe infections caused by sensitive Gram-negative bacilli, such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Serratia, Pseudomonas aeruginosa, and methicillin-sensitive strains of Staphylococcus, such as sepsis, lower respiratory tract infection, intestinal infection, pelvic infection, abdominal infection, skin and soft tissue infection, complicated urinary tract infection, etc. It should be used in combination with anti-anaerobic drugs for the treatment of abdominal and pelvic infections. In clinical practice, gentamicin is often used in combination with other antibacterial drugs. It can be used in combination with penicillin (or ampicillin) to treat enterococcal infections. 2. When used for central nervous system infections caused by sensitive bacteria, such as meningitis and ventriculitis, this product can be used for intrathecal injection as an auxiliary treatment.

1. For adults, intramuscular injection or intravenous drip after dilution, 80 mg (80,000 units) at a time, or 1-1.7 mg/kg per body weight, once every 8 hours; or 5 mg/kg once, once every 24 hours. The course of treatment is 7 to 14 days. When intravenously dripping, add a single dose to 50-200 ml of 0.9% sodium chloride injection or 5% glucose injection. The amount of liquid added during intravenous drip once a day should be no less than 300 ml, so that the concentration of the drug solution does not exceed 0.1%. The solution should be dripped slowly within 30 to 60 minutes to avoid neuromuscular blocking effects. 2. For children, intramuscular injection or intravenous drip after dilution, 2.5 mg/kg once, once every 12 hours; or 1.7 mg/kg once, once every 8 hours. The course of treatment is 7 to 14 days, and blood drug concentrations should be monitored as much as possible during this period, especially for newborns or infants. 3. The dosage for intrathecal and intraventricular administration is 4-8 mg for adults and 1-2 mg for children (over 3 months old), once every 2-3 days. When injecting, dilute the drug solution to a concentration not exceeding 0.2%, draw it into a 5ml or 10ml sterile syringe, and after lumbar puncture, allow a considerable amount of cerebrospinal fluid to flow into the syringe first, and then push while drawing, and slowly inject all the drug solution within 3-5 minutes. 4. Dosage for patients with renal impairment: once every 8 hours for patients with normal renal function, the normal dose is 1-1.7 mg/kg at a time. When the creatinine clearance rate is 10-50ml/min, once every 12 hours, 30-70% of the normal dose; when the creatinine clearance rate is <10ml/min, 20-30% of the normal dose is given every 24-48 hours. 5. After hemodialysis, depending on the severity of the infection, adults can be given a single supplemental dose of 1 to 1.7 mg/kg, and children (over 3 months old) can be given a single supplemental dose of 2 to 2.5 mg/kg.

1. Ototoxic reactions such as hearing loss, tinnitus or fullness in the ears may occur during medication. When vestibular function is affected, unsteady gait and dizziness may occur. Nephrotoxic reactions such as hematuria, significantly reduced urination frequency or urine volume, loss of appetite, and extreme thirst may also occur. Those with lower incidence rates include dyspnea, drowsiness, weakness, etc. caused by neuromuscular blockade or nephrotoxicity. Occasionally, there may be rash, nausea, vomiting, decreased liver function, leukopenia, granulocytopenia, anemia, hypotension, etc. 2. A small number of patients may experience ototoxic symptoms such as hearing loss, tinnitus or fullness in the ears after discontinuation of the drug, which should be paid attention to. 3. Systemic administration combined with intrathecal injection may cause leg twitching, rash, fever, and systemic spasms.

Patients who are allergic to this product or other aminoglycosides are contraindicated.

1. When used in combination with other aminoglycosides or when applied topically or systemically successively, it may increase the possibility of producing ototoxicity, nephrotoxicity and neuromuscular blocking effects. 2. When used in combination with neuromuscular blockers, it may aggravate neuromuscular blocking effects, leading to symptoms such as muscle weakness and respiratory depression. 3. When used in combination with capreomycin, cisplatin, ethacrynic acid, furosemide or vancomycin (or norvancomycin), or when applied topically or systemically successively, it may increase ototoxicity and nephrotoxicity. 4. When used topically or systemically with cephalothin or cefazolin, it may increase nephrotoxicity. 5. When used in combination with polymyxin injections or when applied topically or systemically successively, it may increase nephrotoxicity and neuromuscular blocking effects. 6. Other nephrotoxic and ototoxic drugs should not be used in combination with this product or when applied topically successively, so as not to aggravate nephrotoxicity or ototoxicity. 7. When aminoglycosides and β-lactams (cephalosporins and penicillins) are mixed, they may lead to mutual inactivation. When this product is used in combination with the above antibiotics, it must be dripped in separate bottles. This product should not be dripped in the same bottle with other drugs.

Keep tightly closed in a cool, dark place.

2ml: 40,000 units

Sinopharm Ronshyn Pharmaceutical Co., Ltd.

• Founded in:

  1999-05-06

• Address:

  No. 686, Yingbin Avenue, Wuzhi County, Jiaozuo City, Henan Province

• Tax NO.:

  914108237156088969

• Registered Funds:

  150 million yuan

• Email:

  Log in to view